Direct E-test on Bronchoalveolar Lavage From Patients With Ventilator-acquired Pneumonia
NCT01042353 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2010-01-05
Summary
* Background: Ventilator-acquired pneumonia (VAP) is the most prevalent nosocomial infection in intensive care units (ICUs). Early microbiological diagnosis and initial administration of appropriate antimicrobial therapy are associated with a better outcome. Broad-spectrum antibiotics should therefore be administered initially. However, inconsiderate antibiotic use can increase the prevalence of multi-resistant bacteria.
* Purpose: A rapid antimicrobial susceptibility method is required to decrease the unnecessary use of empirical broad-spectrum antibiotics. The aim of this study is to compare the efficiency of a rapid antibiogram, provided by E-test strips directly applied to bronchoalveolar lavage (BAL) samples and analysed at 24 h, to that obtained with standard methods of culture which provide a later result.
* Study design: This will be an open-label, prospective cohort study of consecutive patients with VAP, conducted in a medical ICU. In addition to standard culture methods, an E-test will be performed directly on BAL samples and analysed at 24 h. Each standard BAL culture will be used as a control for the E-test method.
* Primary outcome: The occurrence of major errors, defined as isolates determined to be susceptible by the E-test but resistant by standard culture methods.
* Secondary outcomes: The occurrence of minor errors (defined as isolates determined to be resistant by the E-test and susceptible by the standard method), and a comparison of two methods of seeding BAL samples on Mueller Hinton agar plates (swabbing method, flooding method).
* Eligibility criteria:
* Inclusion criteria: all patients with suspected VAP (defined by a Clinical Pulmonary Infection Score ≥5) undergoing BAL will be eligible.
* Exclusion criteria: contraindications for BAL (PaO2/FIO2 \<100, risk of bronchoscopy-related haemorrhagic complications), secondary exclusion of patients with negative cultures, defined by a threshold of bacteria \<104 CFU/ml.
* Interventions:
BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures. At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
Conditions
- Ventilator Acquired Pneumonia
Interventions
- PROCEDURE
-
E test
At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
- PROCEDURE
-
standard culture method
BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
Sponsors & Collaborators
-
Université Victor Segalen Bordeaux 2
lead OTHER
Principal Investigators
-
alexandre Boyer, MD · Université Bordeaux 2
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- France
Study Locations
More Related Trials
-
Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients
NCT03413293 ·Status: UNKNOWN
-
How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?
NCT04348227 ·Status: UNKNOWN
-
Delayed Antibiotic Therapy in Non-severe Ventilator Acquired Pneumonia (VAP)
NCT05205525 ·Status: COMPLETED
-
Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit
NCT01878643 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
NCT04839653 ·Status: UNKNOWN ·Phase: NA
-
Pulmonary Diffusion of Antibiotics in Patients Admitted for ARDS Following SARS-CoV-2 Pneumonia
NCT05464680 ·Status: COMPLETED ·Phase: NA
-
Bilateral Bronchoalveolar Lavage in Ventilator-associated Pneumonia
NCT02542553 ·Status: COMPLETED ·Phase: NA
-
Direct Molecular Characterization of Bacteria From ICU and From the REHAB
NCT03475472 ·Status: COMPLETED
-
Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients
NCT04344509 ·Status: UNKNOWN
-
Ventilator Associated Pneumonia Multiplex PCR for Anti-Infective Regimens
NCT06554327 ·Status: RECRUITING ·Phase: NA
-
Airway Microbiome Changes After Artificial Airway Exchange in Critically-ill Pediatric Patients.
NCT06201130 ·Status: RECRUITING
-
Antibiotic Treatment for Pneumonia Caused by Stenotrophomonas Maltophilia in ICU Patients
NCT07052604 ·Status: RECRUITING
-
Prospective Randomized Controlled Multicenter Trial of 4 Antiseptic Strategies for Prevention of Catheter Infection in Intensive Care Unit for Adults Patients
NCT01629550 ·Status: COMPLETED ·Phase: PHASE4
-
Microbiological Profile of VAP Patients in Respiratory ICU
NCT05738928 ·Status: UNKNOWN
-
Impact of Antibiotic Treatment on Outcome in Patients With Ventilator-Associated Tracheobronchitis
NCT00122057 ·Status: COMPLETED ·Phase: NA
-
Oral Care Interventions and Ventilator Associated Pneumonia in Critically Ill Children
NCT01083407 ·Status: COMPLETED ·Phase: PHASE1
-
Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
NCT03303937 ·Status: COMPLETED
-
Predictive Factors of Good Pulmonary Penetration of Antibiotics : AntiBiotics Dosage in Broncho-Alveolar Lavage
NCT03927079 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Impact of BacT/Alert® VIRTUO®, BioFire® Blood Culture Identification 2-BCID2 and REVEAL® (bioMérieux) on the Optimization of Antibiotic Therapy for Gram-negative Bacteremia in the ICU
NCT05741424 ·Status: COMPLETED ·Phase: NA
-
Use of Microscopy, Cultures and Molecular Biological Methods for Diagnosing Nosocomial Pneumonia
NCT04279873 ·Status: COMPLETED
-
Microbial and Pharmacological Assessment of Chlorhexidine
NCT03290105 ·Status: COMPLETED
-
Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU
NCT02413242 ·Status: COMPLETED
-
Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP)
NCT02077920 ·Status: COMPLETED ·Phase: PHASE2
-
Strategies To Prevent Pneumonia 2 (SToPP2)
NCT00893763 ·Status: COMPLETED ·Phase: PHASE2
-
Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?
NCT01875692 ·Status: COMPLETED